DiaMedica Therapeutics, Inc.
NEWS
Minneapolis-based DiaMedica Therapeutics plans to conduct additional studies in order to resolve a clinical hold on its DM199 program for the treatment of acute ischemic stroke (AIS).
DiaMedica Therapeutics’ Phase II/III ReMEDy2 trial is on hold by the FDA because patients were experiencing severe drops in blood pressure.
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.
A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
A summary of IPOs from companies in the biotech and pharma world since November 1, 2018.
JOBS
IN THE PRESS